Targeting Glioblastoma: The Current State of Different Therapeutic Approaches.

Khan I., Mahfooz S., Elbasan E. B., Karacam B., Oztanir M. N., Hatiboglu M. A.

Current neuropharmacology, vol.19, pp.1701-1715, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19
  • Publication Date: 2021
  • Doi Number: 10.2174/1570159x19666210113152108
  • Journal Name: Current neuropharmacology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo
  • Page Numbers: pp.1701-1715
  • Keywords: Glioblastoma, immunotherapy, microRNA, nano-therapy, targeted therapy, viral therapy, CENTRAL-NERVOUS-SYSTEM, ENGINEERED T-CELLS, COMBINATION THERAPY, VIRAL VECTORS, TUMOR-GROWTH, CANCER, BRAIN, TEMOZOLOMIDE, GLIOMA, AMPK
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Background: Glioma is the primary cancer of the central nervous system in adults. Among gliomas, glioblastoma is the most deadly and aggressive form, with an average life span of 1 to 2 years. Despite implementing the rigorous standard care involving maximal surgical removal followed by concomitant radiation and chemotherapy, the patient prognosis remains poor. Due to the infiltrative nature of glioblastoma, chemo-and radio-resistance behavior of these tumors and lack of potent chemotherapeutic drugs, treatment of glioblastoma is still a big challenge. Objective: The goal of the present review is to shed some light on the present state of novel strate-gies, including molecular therapies, immunotherapies, nanotechnology and combination therapies for patients with glioblastoma. Methods: Peer-reviewed literature was retrieved via Embase, Ovid, PubMed and Google Scholar till the year 2020. Conclusion: Insufficient effect of chemotherapies for glioblastoma is more likely because of differ-ent drug resistance mechanisms and intrinsically complex pathological characteristics. Therefore, more advancement in various therapeutic approaches such as antitumor immune response, target-ing growth regulatory and drug resistance pathways, enhancing drug delivery and drug carrier sys-tems are required in order to establish an effective treatment approach for patients with glioblasto-ma.